Orthofix Medical Inc

The asset remains in a Stage 4 decline with confirmed lower highs and lower lows under declining EMAs. Price has been rejected at the 9/20 EMA band repeatedly, reinforcing a medium-term bearish bias. Oversold status does not grant mean-reversion permission, and short-term timing is neutral. Execution should be deferred into future rally attempts into EMA resistance rather than sold immediately. A Trim is recommended to seek a better entry point on a bounce into the EMAs.

• ↑Virada spinal system launch expected to enhance surgical efficiency and penetrate $2B US pedicle screw market.
• ↑Q1 net sales $196.4M, up 3% YoY; top 30 distributors drove 27% growth.
• ↓Medicare reimbursement reversals and FDA reclassification risk could shrink revenue.